BioCentury
ARTICLE | Preclinical News

Fate's CAR Ts show efficacy

April 16, 2018 7:51 PM UTC

Fate Therapeutics Inc. (NASDAQ:FATE) presented data Monday at the American Association for Cancer Research meeting in Chicago showing that its off-the-shelf CAR T cell therapy FT819 elicited an immune response in cell studies.

FT819 cells are developed from an induced pluripotent stem cell (iPS cell) line and are engineered to lack a T cell receptor (TCR) and to dually target CD19 and Fc gamma receptor III (CD16; FCGR3)...